The Steroid-Sparing Effect of Adalimumab in the Treatment for the Recurrent Phase of Vogt–Koyanagi–Harada Disease

References

• Sonoda K, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H. JOIS (Japanese Ocular Inflammation Society) uveitis survey working group: epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65(2):184–190. doi:10.1007/s10384-020-00809-1.
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Taguchi C, et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci. 2006;47(6):2547–2554. doi:10.1167/iovs.05-1547.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kokubo T, Takahashi M, et al. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics. 1998;47(5):398–403. doi:10.1007/s002510050375.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Denniston AK, Dick AD, et al. Standardization of uveitis nomenclature (SUN) working group: classification criteria for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2021;9(228):205–211.
   Google Scholar
• Nakayama M, Keino H, Watanabe T, Okada AA. Clinical features and visual outcomes of 111 patients with Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol. 2019;103(2):274–278. doi:10.1136/bjophthalmol-2017-311691.
   PubMed Web of Science ®Google Scholar
• Read RW, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi- Harada disease. Am J Ophthalmol. 2006;142(1):119–124. doi:10.1016/j.ajo.2006.02.049.
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A, Bascal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147(1):154–161. doi:10.1016/j.ajo.2008.07.044.
   PubMed Web of Science ®Google Scholar
• Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond). 2009;23(3):543–548. doi:10.1038/eye.2008.89.
   PubMed Web of Science ®Google Scholar
• Errara MH, Fardeau C, Cohen D, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2011;89(4):357–366. doi:10.1111/j.1755-3768.2010.02055.x.
   Web of Science ®Google Scholar
• Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27(2–3):137–142. doi:10.1007/s10792-006-9009-6.
   PubMedGoogle Scholar
• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2010;30(1):41–50. doi:10.1007/s10792-008-9288-1.
   PubMedGoogle Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–584. doi:10.1016/j.ophtha.2009.08.010.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–194. doi:10.1136/ard.2007.072967.
   PubMed Web of Science ®Google Scholar
• Couto C, Schlaen A, Frick M, et al. Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2018;26(3):485–489. doi:10.1080/09273948.2016.1236969.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group: standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of Vogt-koyanagi-Harada disease. J Ophthalmic Vis Res. 2011;6:241–248.
   PubMedGoogle Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294. doi:10.1097/00004836-200110000-00006.
   PubMed Web of Science ®Google Scholar
• Lee SH, Chung H, Yu HG. Clinical outcomes of cyclosporine treatment for noninfectious uveitis. Korean J Ophthalmol. 2012;26(1):21–25. doi:10.3341/kjo.2012.26.1.21.
   PubMedGoogle Scholar
• Robert N, Wong GW, and Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;20(1). doi:10.1002/14651858.CD007893.
   Google Scholar
• Takayama K, Obata H, Takeuchi M. Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy. Ocul Immunol Inflamm 2020 2;28(3):509–512. doi:10.1080/09273948.2019.1603312.
   PubMed Web of Science ®Google Scholar
• Miyasaka N. CHANGE study investigators: clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with Adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3):252–262. doi:10.3109/s10165-008-0045-0.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 study group: adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310. doi:10.1111/j.1346-8138.2009.00748.x.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Study investigators: adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6(2):160–173. doi:10.1016/j.crohns.2011.07.013.
   PubMed Web of Science ®Google Scholar
• Liberman P, Berkenstock MK, Burkholder BM, Chaon BC, Thorne JE. Escalation to weekly adalimumab for the treatment of ocular inflammation. Ocul Immunol Inflamm. 2020;14:1–5. doi:10.1080/09273948.2020.1808227.
   Google Scholar
• Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007;15(5):381–387. doi:10.1080/09273940701624312.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW. AI-Muammar A: mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2017;95(1):85–90. doi:10.1111/aos.13189.
   PubMed Web of Science ®Google Scholar
• Bordaberry MF. Vogt-Koyanagi-Harada disease: diagnosis and treatments update. Curr Opin Ophthalmol. 2010;21(6):430–435. doi:10.1097/ICU.0b013e32833eb78c.
   PubMed Web of Science ®Google Scholar
• Yang P, Ye Z, Du L, et al. Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents. Curr Eye Res. 2018;43:254–261.
   PubMed Web of Science ®Google Scholar